VDPHL01
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Androgenetic Alopecia
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Trial Timeline
Jul 8, 2024 → Aug 1, 2026
NCT ID
NCT06527365About VDPHL01
VDPHL01 is a phase 2 stage product being developed by Veradermics for Androgenetic Alopecia. The current trial status is active. This product is registered under clinical trial identifier NCT06527365. Target conditions include Androgenetic Alopecia, AGA, Male Pattern Baldness.
What happened to similar drugs?
0 of 7 similar drugs in Androgenetic Alopecia were approved
Approved (0) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06527365 | Phase 2 | Active |
Competing Products
12 competing products in Androgenetic Alopecia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| minoxidil | Johnson & Johnson | Phase 3 | 40 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 35 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 40 |
| Cyproterone Acetate (Androcur, BAY94-8367) | Bayer | Pre-clinical | 23 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 37 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 41 |
| VDPHL01 QD + Placebo + VDPHL01 BID + Placebo | Veradermics | Phase 3 | 41 |
| VDPHL01 + Placebo | Veradermics | Phase 2/3 | 36 |
| VDPHL01 + Placebo | Veradermics | Phase 3 | 38 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Organon | Phase 3 | 34 |
| ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection | AbSci | Phase 1/2 | 29 |
| ATI-50002 | Aclaris Therapeutics | Phase 2 | 25 |